Akero Therapeutics' Disappointing NASH Data Drags Its Rival
Portfolio Pulse from Vandana Singh
Akero Therapeutics reported disappointing 36-week analysis of its Phase 2b study of efruxifermin in patients with nonalcoholic steatohepatitis (NASH), causing its shares to tumble. The news also negatively impacted shares of its rival 89bio, which is developing a similar treatment for NASH.
October 10, 2023 | 6:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akero's disappointing study results have caused its shares to fall.
Akero's shares fell due to the disappointing results of its Phase 2b study of efruxifermin in NASH patients. This negative news directly impacts the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Shares of 89bio also fell due to the disappointing results from Akero's study.
89bio's shares fell in response to the disappointing results from Akero's study. As both companies are developing similar treatments for NASH, negative news from one can impact the other.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80